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treatment targets for survival and renal outcome.
OBJECTIVES This study sought to evaluate ranges of treated BP in a large hypertension population and compare risk
of mortality and end-stage renal disease (ESRD).
METHODS A retrospective cohort study within the Kaiser Permanente Southern California health system was performed
from January 1, 2006, to December 31, 2010. Treated hypertensive subjects $18 years of age were studied. Cox
proportional hazards regression models were used to evaluate the risks (hazard ratios) for mortality and/or ESRD among
different BP categories with and without stratiﬁcation for diabetes mellitus and older age.
RESULTS Among 398,419 treated hypertensive subjects (30% with diabetes mellitus), mortality occurred in 25,182
(6.3%) and ESRD in 4,957 (1.2%). Adjusted hazard ratios (95% conﬁdence intervals [CI]) for composite mortality/ESRD
in systolic BP <110, 110 to 119, 120 to 129, 140 to 149, 150 to 159, 160 to 169, and $170 compared with 130 to 139
mm Hg were 4.1 (95% CI: 3.8 to 1.3), 1.8 (95% CI: 1.7 to 1.9), 1.1 (95% CI: 1.1 to 1.1), 1.4 (95% CI: 1.4 to 1.5), 2.3 (95% CI:
2.2 to 2.5), 3.3 (95% CI: 3.0 to 3.6), and 4.9 (95% CI: 4.4 to 5.5) respectively. Diastolic BP 60 to 79 mm Hg were
associated with the lowest risk. The nadir systolic and diastolic BP for the lowest risk was 137 and 71 mm Hg, respectively.
Stratiﬁed analyses revealed that the diabetes mellitus population had a similar hazard ratio curve but a lower nadir at
131 and 69 mm Hg but age $70 had a higher nadir (140 and 70 mm Hg).
CONCLUSIONS Both higher and lower treated BP compared with 130 to 139 mm Hg systolic and 60 to 79 mm Hg
diastolic ranges had worsened outcomes. Our study adds to the growing uncertainty about BP treatment targets.
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ABB R E V I A T I O N S
AND ACRONYMS
BMI = body mass index
BP = blood pressure
CCI = Charlson comorbidity
index
CI = conﬁdence interval
CKD = chronic kidney disease
DBP = diastolic blood pressure
DM = diabetes mellitus
eGFR = estimated glomerular
ﬁltration rate
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589and mortality outcomes. Lower observed BP across
all age groups have been associated with the greatest
morbidity and survival beneﬁts (3). These observa-
tions have led to conclusions that lowering BP along
that linear axis will correspond with a proportionate
decrease in risk (4). The perception has been the
same for the risk of renal failure (5). Indeed, signiﬁ-
cant risk reductions have been demonstrated in pro-
spective interventional studies that have lowered
BP in those with severe HTN (5–13). However, aggres-
sive BP lowering has not convincingly shown beneﬁt
(14–19) and may actually predispose individuals to
harm (20–24).Kaiser Permanente Southern California
3.4 Million Members
(1/1/06-12/31/07)
Children 2.4 Million adults age>17
years
498,249 Hypertensive
Members
459,018
Hypertensive
Members
60,599
Untreated
27,863 with missing blood
pressures 11,368 no followup
EXCLUDED
Non Hypertensive
Members
398,419 MedicallyTreated
Hypertension
FIGURE 1 KPSC Treated Hypertension Study Cohort
A total of 398,419 hypertensive patients met inclusion criteria, meaning that they were
treated with hypertensive medicines and had documented blood pressures during the
period of follow-up to December 31, 2010. KPSC ¼ Kaiser Permanente Southern California.
SEE PAGE 598
ESRD = end-stage renal
disease
HR = hazards ratio
HTN = hypertension
ICD-9 = International
Classiﬁcations of Diseases-
Ninth Revision
KPSC = Kaiser Permanente
Southern California
SBP = systolic blood pressureIn high-risk populations, such as those with dia-
betes mellitus (DM) and chronic kidney disease (CKD),
interventions to lower BP below current target levels
have not demonstrated outcome improvements
(14,19,25). In fact, aggressive BP lowering has been
associated with worsened outcomes (20–22), which is
suggestive of a J-shaped curve. This nonlinear curve is
similar to what has already been observed in other
cardiovascular disease risk factors (24,26). Thus, for
the treated general HTN population, the relationship
between treated BP and outcomes is not well-deﬁned.
We used a large ethnically diverse population of sub-
jects who were medically treated for HTN to evaluate
discrete ranges of achieved BP and subsequent risk
for mortality and end-stage renal disease (ESRD).
METHODS
A retrospective cohort study was performed among
members of Kaiser Permanente Southern California
(KPSC) during the period January 1, 2006, through
December 31, 2010. KPSC is an integrated health sys-
tem composed of 14 medical centers and >200 satel-
lite medical ofﬁces, with a membership exceeding
3.5 million people. The membership population is
ethnically and socioeconomically diverse, reﬂecting
the population of the state of California (27). KPSC
complete healthcare encounters are tracked using a
common electronic health record and are collected
as part of routine clinical care encounters. The KPSC
Institutional Review Board approved the study pro-
tocol, which was exempt from informed consent.
The study population consisted of subjects $18
years of age who had a minimum of 6 months of
continuous membership in the health plan. The HTN
study cohort was identiﬁed in a 2-year window
(January 1, 2006, to December 31, 2007) and followed
up to December 31, 2010. HTN was identiﬁed as
any member with 2 International Classiﬁcations ofDiseases-Ninth Revision (ICD-9) codes, spe-
ciﬁc to HTN (401.xx, 402.xx, 403.xx, 404.xx,
405.xx). The accuracy of ICD-9 coding for the
diagnosis of HTN has been previously vali-
dated (28). Recorded BP values at baseline
when the cohort was initially identiﬁed and
all subsequent BP were retrieved. Inclusion
criteria were hypertensive patients who had
a minimum of 1 outpatient BP measurement
and documented prescription(s) for antihy-
pertensive medications. Patients were de-
termined to be on an antihypertensive
medication if it was prescribed and ﬁlled
for $7 days within the observation period.
Exclusion criteria were subjects <18 years of
age, who were on dialysis, or who had
received a renal transplant, with no docu-
mented diagnosis of HTN, no documented
BP, or no documented prescription for anti-
hypertensive medications. Patients with con-
gestive heart failure also were excluded as
their BP may not necessarily reﬂect treated
BP values.Comorbidities, including DM, ischemic heart dis-
ease, congestive heart failure, and cerebrovas-
cular disease, were determined on the basis of
inpatient and outpatient ICD-9 diagnoses codes. CKD
TABLE 1 Characteristics of Treated Hypertension Cohort
All
(N ¼ 398,419)
<110
mm Hg
(n ¼ 6,531)
110–119
mm Hg
(n ¼ 43,865)
120–129
mm Hg
(n ¼ 138,958)
130–139
mm Hg
(n ¼ 141,582)
140–149
mm Hg
(n ¼ 49,463)
150–159
mm Hg
(n ¼ 12,682)
160–169
mm Hg
(n ¼ 3,641)
$170
mm Hg
(n ¼ 1,697) p Value
Age, yrs 64 66  11 64  11 64  10 65  11 65  11 66  12 65  12 66  11 <0.001
Median age, yrs 63 64 62 63 64 64 64 63 64
Female 55 43 49 54 58 60 61 61 61 <0.001
Race <0.001
White 41 51 46 43 41 37 33 27 28
Black 12 7 8 11 13 16 20 22 22
Hispanic 21 19 20 20 21 23 23 23 24
Asian/Paciﬁc 8 10 10 9 7 6 5 5 5
Other 17 13 15 17 17 18 19 22 21
Blood pressure, mean
SBP, mm Hg 131 106 116 126 134 144 154 164 179
DBP, mm Hg 73 63 68 72 75 77 80 84 89
BMI $30 kg/m2 43 26 36 43 45 46 45 44 38 <0.001
Creatinine, mg/dl 1.0  0.4 1.1  0.5 1.0  0.4 1.0  0.3 1.0  0.3 1.0  0.4 1.0  0.5 1.1  0.7 1.2  0.8 <0.001
eGFR, ml/min/1.73 m2 74  20 72  21 74  20 75  19 74  19 73  20 72  22 71  22 68  23 <0.001
Chronic kidney disease* 24 28 24 23 23 26 28 29 33 <0.001
Diabetes mellitus 30 40 36 32 27 29 33 34 33 <0.001
Ischemic heart disease 19 43 39 27 16 10 8 9 19 <0.001
Cerebrovascular disease 8 25 19 12 7 4 4 5 8 <0.001
Values are % or mean  SD. *Deﬁned as eGFR <60 ml/min/1.73 m2.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; SBP ¼ systolic blood pressure.
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590was deﬁned as an estimated glomerular ﬁltration
rate (eGFR) <60 ml/min/1.73 m2, calculated from
serum creatinine levels and the CKD Epidemiology
Collaboration equation (29). Obesity was deﬁned as-120 120-130 130-140 140-150
Systolic Blood Pressure
Continuous Adjusted HR for Mortality/ESRD
150-160 160-170 >170
ous HR for Mortality/ESRD Across SBP
r mortality/end-stage renal disease (ESRD) with 95% conﬁdence
ystolic blood pressure (SBP) associated with the lowest risk was
Hg. A test on the relationship between the HR and quadratic term of
s gave a signiﬁcant result for nonlinearity (p < 0.001).a body mass index (BMI) $30. Charlson comorbidity
index (CCI) scores also were calculated for each
subject.
KAISER PERMANENTE HTN MANAGEMENT. Since
2005, KPSC has internally advocated and made
available a simpliﬁed HTN treatment algorithm to
guide therapy for all practitioners treating and man-
aging HTN (30). We have previously described that a
majority of the practitioners within KPSC follow the
algorithm as demonstrated by medication prescrip-
tion information (30–32). During the study period,
HTN control rates in the KPSC population ranged
from 65% to 80% (30–32).
OUTCOMES. The primary outcome evaluated was a
composite of mortality or ESRD. Because mortality is
a strong competing risk for subjects who progress to
ESRD (33), the composite outcome was studied to
minimize confounding of mortality on ESRD. ESRD,
deﬁned as treatment with dialysis or renal trans-
plantation, is captured within an internal KPSC
database that includes all dialysis and renal trans-
plant patients along with comprehensive clinical care
information. Mortality information was obtained
from hospitalization records, outside billing records,
state vital statistics, and Social Security Administra-
tion death ﬁles. For the latter 2 sources, a probabilistic
match was made on the basis of name, address, birth
date, Social Security Number (when available), and
TABLE 2 Crude Event Rates per SBP and Length of Follow-Up
All <110 110-119 120-129 130-139 140-149 150-159 160-169 $170
Event
Mortality 25,182 1,396 4,101 7,659 6,837 3,286 1,244 405 254
6.3 21.5 9.3 5.5 4.8 6.7 9.9 11.4 15.8
ESRD 4,957 159 486 1,166 1,381 1,010 435 203 117
1.2 2.4 1.1 0.8 1.0 2.0 3.4 5.6 6.9
Mortality/ESRD 28,919 1,494 4,402 8,486 7,908 4,107 1,595 571 356
7.3 22.9 10.0 6.1 5.6 8.3 12.6 15.7 21.0
Length of follow-up, yrs
Median 4.5 4.1 4.5 4.5 4.5 4.4 4.1 3.8 3.0
Mean 4.0 3.5 4.0 4.1 4.1 3.9 3.5 3.2 2.8
Values are n or %.
ESRD ¼ end-stage renal disease; SBP ¼ systolic blood pressure.
TABLE 3 Crude and Adjusted Hazards Ratios for Mortality/ESRD by SBP
Multivariate Cox Regression Analysis
(95% CI) for Mortality/ESRD by SBP
p Value
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Systolic blood pressure, mm Hg
<110 5.00 (4.73–5.28) 4.10 (3.87–4.33)* <0.001
110-119 1.86 (1.79–1.93) 1.81 (1.74–1.88) <0.001
120-129 1.08 (1.05–1.11) 1.12 (1.08–1.15) <0.001
130-139 — — —
140-149 1.61 (1.55–1.67) 1.44 (1.39–1.50) <0.001
150-159 2.80 (2.65–2.95) 2.34 (2.22–2.47) <0.001
160-169 3.97 (3.64–4.32) 3.33 (3.05–3.63) <0.001
$170 6.41 (5.75–7.13) 4.91 (4.41–5.47) <0.001
Age (every 5-yr increase) 1.49 (1.48–1.50) 1.40 (1.39–1.41) <0.001
Male vs. female 1.28 (1.25–1.31) 1.33 (1.30–1.37) <0.001
Black vs. white 1.08 (1.04–1.11) 1.23 (1.18–1.27) <0.001
DM 1.50 (1.46–1.54) 1.57 (1.37–1.61) <0.001
CKD 3.13 (3.06–3.20) 1.40 (1.53–1.43) <0.001
Cerebrovascular disease 2.75 (2.67–2.83) 1.46 (1.41–1.50) <0.001
Ischemic heart disease 2.16 (2.11–2.22) 1.25 (1.22–1.28) <0.001
*Adjusted hazards ratios were estimated with adjustment for age, sex, race, BMI $30 kg/m2, CKD, DM and
comorbidities of ischemic heart disease, and cerebrovascular disease.
CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; DM ¼ diabetes mellitus; ESRD ¼ end-stage renal
disease; HR ¼ hazard ratio.
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591other demographic information. Because data from
these latter sources may be delayed, December 31,
2010, was used to censor follow-up.
Secondary outcomes included ESRD and mortality
separately as competing risks and in stratiﬁed ana-
lyses of those with or without DM, age <70 or $70
years, and CCI scores.
The arithmetic means of all outpatient BP values
were used in the analyses. The values were then
categorized into systolic blood pressure (SBP) in-
crements of 10 mm Hg in the following manner: <110,
110 to 119, 120 to 129, 130 to 139, 140 to 149, 150 to 159,
160 to 169, $170. Similar analyses were performed
using diastolic BP (DBP) increments of 10 mm Hg in
the following manner: <50, 50 to 59, 60 to 69, 70 to
79, 80 to 89, 90 to 99, and $100. Differences in
the distributions of continuous and ordinal variables
were tested using the Kruskal-Wallis test and for
categorical variables, the chi-square test. Given the
large size of the population and data, no imputations
were performed for any missing values (e.g., eGFR).
Cox proportional hazards regression models were
used to calculate hazard ratios (HR) among different
SBP categories for mortality, ESRD, and the compos-
ite of mortality/ESRD. The 130 to 139 and 80 to
89 mm Hg categories were used as the reference
category for SBP and DBP, respectively. Adjusted HR
were estimated adjusting for age, sex, race, BMI $30,
CKD, DM, and comorbidities of ischemic heart dis-
ease and cerebrovascular disease. Proportionality
assumptions were tested by both graphic approaches
and the addition of interaction terms with time. A
cubic spline smoothing technique was used to inter-
polate the overall trend of risks through the range of
BP. To determine the nadir where the risk is lowest, a
secondary analysis was performed by treating SBP/
DBP as continuous variables and included a quadratic
term. These analyses were repeated in subgroups onthe basis of DM status, age, and CCI scores. All sta-
tistical analyses were performed using SAS (version
9.2, SAS Institute Inc., Cary, North Carolina) statisti-
cal software. Results with p values <0.05 were
considered statistically signiﬁcant.
SENSITIVITY ANALYSIS. We performed sensitivity
analyses using single baseline BP deﬁned as the
values closest in date to the second ICD-9–coded HTN
date. Subgroup analyses also were performed in
those who died. BP values within 60 days of death
were excluded to control for any residual confound-
ing on BP from end of life. The mean BP before
and within 60 days of death were also compared.
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FIGURE 3 Continuous HR Across DBP
HR for mortality/ESRD, mortality alone, and ESRD alone with
95% conﬁdence intervals. DBP ¼ diastolic blood pressure; other
abbreviations as in Figure 2.
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592Different subpopulations were considered in
additional sensitivity analyses. We performed sepa-
rate analyses after removing those with eGFR<60 ml/
min./1.73 m2, thereby removing the confounding of
CKD itself on ESRD/mortality risk. We also tested
whether there was an interaction between pre-
existing cardiovascular disease and BP on the out-
comes studied. If there were signiﬁcant interactions,
BP variables were evaluated in those with and with-
out cardiovascular disease. We also performed sepa-
rate analyses, excluding all patients with cancer or
dementia diagnoses as deteriorating health status
may confound the BP relationship.RESULTS
A total of 398,419 treated hypertensive patients were
identiﬁed for the study cohort and analyses (Fig. 1). At
baseline, the mean age of the population was 64
years. The cohort was composed of 55% women, 41%
whites, 12% blacks, and 21% Hispanics (Table 1).
The mean BP for the cohort was 131/73 mm Hg with
standard deviations for SBP (11 mm Hg) and DBP
(8 mm Hg), respectively. In those who died, the mean
SBP decreased 7 mm Hg during the 60 days before
death (124 vs. 131 mm Hg [p < 0.01]). DBP differences
were not as pronounced with a decrease of 3 mm Hg
(70 mm Hg before and 67 mm Hg within 60 days of
mortality [p < 0.01]).
Overall, 83% of the HTN population was consid-
ered controlled (<140 mm Hg) during the observation
period. BMI information was available in 99% of the
study cohort (4,397 with missing BMI) and 43% were
considered obese. The prevalence of comorbidities
were as follows: DM 30%; ischemic heart disease 19%;
and cerebrovascular disease 8%. The mean serum
creatinine and eGFR of the cohort were 1.0 mg/dl and
74 ml/min/1.73 m2, respectively. Overall, 24% of the
population had an eGFR below 60 ml/min/1.73 m2.
Medications administered to the patient cohort
were generally reﬂective of the KPSC HTN treatment
guidelines (Online Table 1, Online Figure 1). Diuretic
agents (80%), angiotensin-converting enzyme in-
hibitors (70%), beta-blockers (44%), and calcium
channel blockers (37%) were the most frequently
used antihypertensive medications.
EVENT RATES. A total of 28,919 subjects (7.3%) in
the cohort reached the composite outcome of mor-
tality or ESRD (Table 2). The mean and median
lengths of follow-up were 4.0 and 4.5 years, res-
pectively. The lowest and highest SBP groups had the
greatest rates of mortality/ESRD (22.9% and 15.7%).
Accounting for events separately, mortality occurred
in 25,182 (6.3%), whereas ESRD occurred in 4,957
(1.2%). Mortality rates were higher in the lowest and
highest SBP as well. ESRD rates, however, appeared
to increase across higher SBP categories (6.9% of
subjects $170 mm Hg). By contrast, there did
not appear to be a disproportionate increase in
ESRD with the lowest SBP groups (3.4% of subjects
<110 mm Hg).
MULTIVARIABLE REGRESSION ANALYSES. Adjusted
HR for composite mortality/ESRD outcomes using
SBP 130 to 139 mm Hg as the reference demonstrated
greater risk with higher and also lower SBP (Fig. 2,
Table 3). With SBP modeled as a continuous variable
and using a quadratic term, the calculated nadir for
TABLE 4 Adjusted HR on the Basis of DBP
Multivariate Cox Regression Analysis (95% CI) by DBP
Mortality/ESRD Mortality ESRD
Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI)
Diastolic blood
pressure, mm Hg
<50 3.14 (2.73–3.61) 3.32 (2.88–3.83) 2.54 (1.65–3.90)
50–59 0.96 (0.91–1.02) 0.98 (0.92–1.04) 1.12 (0.98–1.27)
60–69 0.72 (0.69–0.76) 0.73 (0.69–0.76) 0.82 (0.74–0.90)
70–79 0.70 (0.67–0.73) 0.71 (0.68–0.74) 0.72 (0.66–0.79)
80–89 — — —
90–99 1.92 (1.73–2.13) 1.99 (1.77–2.24) 1.56 (1.26–1.92)
$100 3.83 (3.04–4.83) 3.65 (2.77–4.80) 3.30 (2.18–5.00)
Adjusted HR were estimated with adjustment for age, sex, race, BMI $30 kg/m2, CKD, DM and comorbidities
of ischemic heart disease, and cerebrovascular disease.
Abbreviations as in Tables 1 and 2.
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FIGURE 4 Continuous HR for Mortality and ESRD Across SBP
HR for mortality and ESRD with 95% conﬁdence intervals. Abbreviations as in Figure 2.
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593mortality/ESRD was 137 mm Hg. DBP revealed a
wider range of optimal outcomes. Compared with
DBP 80 to 89, the adjusted HR were lower for the
range of 60 to 79. DBP both lower and higher than
the 60 to 79 range demonstrated worse outcomes
(Table 4, Fig. 3). The nadir DBP was estimated to be
71 mm Hg. After removing those with cancer and
dementia and then further adjusting for CCI scores
(0, 1, and $2), eGFR, and BMI as continuous vari-
ables, the mortality/ESRD HR were 3.80 (95% con-
ﬁdence interval [CI]: 3.52 to 4.11), 1.72 (95% CI: 1.63
to 1.80), 1.10 (95% CI: 1.06 to 1.15) 1.50 (95% CI: 1.43
to 1.58), 2.44 (95% CI: 2.27 to 2.62), 3.22 (95% CI:
2.88 to 3.61), and 5.02 (95% CI: 4.34, to 5.80) for
SBP <110, 110 to 119, 120 to 129, 140 to 149, 150 to
159, 160 to 169, and >169 mm Hg, respectively
compared with mortality/ESRD HR associated with
SBP 130 to 139 mm Hg.
The mortality-only analyses revealed a similar
U-shaped trend (Fig. 4, Online Table 2). The ESRD-
only analyses suggested a more linear relationship
(Fig. 4, Online Table 3). After removing those with
cancer and dementia and then further adjusting for
CCI scores (0, 1, and $2), eGFR, and BMI as contin-
uous variables, the mortality HR were 4.26 (95% CI:
3.92 to 4.63), 1.95 (95% CI: 1.84 to 2.05), 1.19 (95% CI:
1.14 to 1.25), 1.34 (95% CI: 1.27 to 1.42), 2.12 (95% CI:
1.95 to 2.30), 2.43 (95% CI: 2.12 to 2.80), 3.72 (95%
CI: 3.10 to 4.48) for SBP <110, 110 to 119, 120 to 129,
140 to 149, 150 to 159, 160 to 169, and >169 mm Hg,
respectively compared with the mortality HR associ-
ated with SBP 130 to 139 mm Hg.
STRATIFIED ANALYSES. HR for mortality/ESRD
in patients with DM, compared with nondiabeticpatients, were shifted to lower BP experiencing better
outcomes. The nadir BP in patients with DM were 131
and 69 mm Hg for SBP and DBP, respectively, as
compared with 142 and 73 mm Hg in nondiabetic
patients (Table 5).
When mortality alone was evaluated, nondiabetic
patients appeared to have better survival in the
higher ranges of BP than did the diabetic subpop-
ulation (Fig. 5, Online Table 4). For the ESRD-
only analyses, persons with DM, compared with
nondiabetic patients, experienced better outcomes in
the lower ranges of BP. However, persons with DM
did worse with higher BP than did those without DM
(Online Table 5).
AGE. The estimated nadirs of BP for mortality/ESRD
in age $70 years were 140 and 70 mm Hg for SBP
and DBP, compared with younger subjects whose
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FIGURE 5 Continuous HR Across SBP Stratiﬁed by DM Status
Stratiﬁed analyses comparing continuous HR in those with and
without diabetes mellitus (DM). For the composite mortality/
ESRD outcome, the nadir SBP was 131 in DM patients and
142 mm Hg in non-DM patients. Abbreviations as in Figure 2.
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594nadirs were 133 and 76 mm Hg. For ESRD risk alone,
the age <70 years group fared better with lower
BP ranges compared with those age $70 years
but were more susceptible with higher BP (Online
Table 5).
CHARLSON COMORBIDITY INDEX. Compared with a
CCI score of 1, the adjusted mortality/ESRD HR were
0.43 (95% CI: 0.28 to 0.65) for CCI score of 0 and 1.49
(95% CI: 1.16 to 1.92) for CCI scores of 2 or higher.
Adjusted mortality/ESRD HR within subjects with CCI
scores of 0, 1, and 2 or higher continued todemonstrate a similar BP curve. Mortality/ESRD HR
for those with CCI 0 were 1.15, 0.49, 1.58, 2.54, 1.52,
and 2.29 for SBP 110 to 119, 120 to 129, 140 to 149, 150
to 159, 160 to 169, and >169 mm Hg, respectively. For
CCI 1, the mortality/ESRD HR were 22.32, 1.64, 0.80,
1.24, 2.40, 7.31, and 9.16 compared with those with
CCI 2 or higher, where the mortality/ESRD HR were
3.78, 1.72, 1.10, 1.50, 2.44, 3.21, and 5.01 for SBP <110,
110 to 119, 120 to 129, 140 to 149, 150 to 159, 160 to
169, and >169 mmHg, respectively compared to 130
to 139 mm Hg, respectively (Online Table 6).
SENSITIVITY ANALYSES. Baseline Versus Averaged BP.
Using single baseline BP, the multivariable adjusted
HR for ESRD/mortality compared with SBP 130 to 139
mm Hg were 1.47 (95% CI: 1.39 to 1.55), 1.15 (95% CI:
1.09 to 1.21), 1.02 (95% CI: 0.97 to 1.07) 1.08 (95% CI:
1.02 to 1.14), 1.20 (95% CI: 1.13 to 1.28), 1.21 (95% CI:
1.12 to 1.31), and 1.52 (95% CI: 1.41 to 1.63) for
SBP <110, 110 to 119, 120 to 129, 140 to 149, 150 to 159,
160 to 169, and >169 mm Hg, respectively. Mortality-
alone HR were 1.74 (95% CI: 1.63 to 1.85), 1.27 (95% CI:
1.19 to 1.35), 1.06 (95% CI: 1.00 to 1.12), 1.04 (95% CI:
0.97 to 1.11), 1.12 (95% CI: 1.04 to 1.21), 1.10 (95%
CI: 1.00 to 1.21), and 1.28 (95% CI: 1.16 to 1.40). ESRD-
alone HR were 1.07 (95% CI: 0.98 to 1.18), 0.95 (95%
CI: 0.87 to 1.04), 0.96 (95% CI: 0.88 to 1.04), 1.11
(95% CI: 1.02 to 1.21), 1.27 (95% CI: 1.15 to 1.40), 1.39
(95% CI: 1.23 to 1.56), and 1.8 (95% CI: 1.64 to 2.02)
for the same BP ranges. After removing BP within
60 days of those who experienced mortality or ESRD
event, the adjusted HR revealed a similar trend with
mortality/ESRD HR of 3.84 (95% CI: 3.62 to 4.07),
1.77 (95% CI: 1.71 to 1.84), 1.10 (95% CI: 1.07 to 1.14),
1.46 (95% CI: 1.40, to 1.52), 2.36 (95% CI: 2.23 to
2.49), 3.24 (95% CI: 2.96 to 3.54), and 4.72 (95% CI:
4.20 to 5.31) for SBP <110, 110 to 119, 120 to 129, 140
to 149, 150 to 159, 160 to 169, and >169 mm Hg,
respectively.
Pre-exist ing cardiovascular disease. When tested,
the interactions between ischemic heart disease
and BP were signiﬁcant for mortality (p < 0.001) and
combined mortality/ESRD (p < 0.001). The interaction
between cerebrovascular disease and BP were signiﬁ-
cant for mortality/ESRD only (p ¼ 0.02). HR
for mortality/ESRD outcomes were performed in
those with and without pre-existing ischemic heart
disease and also in those with and without cerebro-
vascular disease. Compared with those without car-
diovascular disease and SBP 130 to 139 mm Hg,
the mortality/ESRD HR in those with pre-existing
ischemic heart disease were 4.19, 2.21, 1.43, 1.36,
2.03, 3.73, 4.38, and 7.69; and in those with pre-
existing cerebrovascular disease, the mortality/ESRD
TABLE 5 Stratiﬁed Analysis: HR for Mortality/ESRD
Multivariate Cox Regression Analysis (95% CI) for Mortality/ESRD by SBP
(Adjusted for Age, Race, Sex, DM, HTN)
DM Nondiabetes Age <70 yrs Age $70 yrs
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
Systolic blood
pressure
<110 3.50 (3.20–3.82) 4.62 (4.30–4.98) 3.92 (3.55–4.32) 4.13 (3.86–4.42)
110–19 1.43 (1.35–1.52) 2.12 (2.02–2.22) 1.64 (1.54–1.75) 1.90 (1.81–1.99)
120–129 0.97 (0.92–1.02) 1.23 (1.18–1.28) 1.02 (0.96–1.07) 1.19 (1.14–1.24)
130–139 — — — —
140–149 1.68 (1.58–1.78) 1.29 (1.22–1.35) 1.62 (1.52–1.73) 1.33 (1.27–1.39)
150–159 2.82 (2.59–3.04) 1.98 (1.84–2.13) 2.94 (2.69–3.22) 1.99 (1.86–2.13)
160–169 4.38 (3.89–4.93) 2.53 (2.23–2.86) 4.72 (4.13–5.39) 2.56 (2.28–2.86)
$170 6.85 (5.88–7.98) 3.73 (3.20–4.35) 8.24 (6.99–9.72) 3.46 (3.00–3.98)
HTN ¼ hypertension; other abbreviations as in Tables 1 and 2.
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CENTRAL ILLUSTRATION Where Is the Ideal BP in Those Treated for Hypertension?
Cubic spline smoothing on the basis of multivariable Cox regression analyses
demonstrating mortality/end-stage renal disease hazard ratios across ranges of blood
pressure (BP). Achieved systolic blood pressure (SBP) range 130 to 139 and diastolic blood
pressure (DBP) range 60 to 79 mm Hg were associated with the best outcomes.
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595HRwere 6.18, 2.33, 1.63, 1.44, 2.06, 2.74, 4.05, and 4.77
for SBP<110, 110 to 119, 120 to 129, 130 to 139, 140 to 149,
150 to 159, 160 to 169, and >169 mm Hg, respectively
(Online Table 7).
CKD. Every 10 ml/min/1.73 m2 decline in eGFR was
associated with a mortality/ESRD HR of 1.08 (95%
CI: 1.07 to 1.09). Sensitivity analyses were performed
after removing subjects with eGFR<60 ml/min/
1.73 m2 to examine the impact of pre-existing CKD.
Essentially similar associations were observed when
the CKD population was removed from the analyses
(data not shown). Less than 1% (2,922) of the popu-
lation had missing eGFR values. Urine protein quan-
titation was not performed or it was unavailable for
the majority of the population (>80%).
DISCUSSION
This observational study of a large diverse cohort of
persons with medically treated HTN demonstrates
that achieved BP in both relatively higher and lower
ranges are associated with worsened risk of mortality
and ESRD. We observed a U-shaped curve for the
composite outcome of mortality/ESRD at SBP >139
and <130 mm Hg (Central Illustration). There were
incremental risk increases in both directions.
DBP <60 and >79 mm Hg similarly had greater risk.
The nadir BP associated with the best outcome were
137 mm Hg for systolic and 71 mm Hg for diastolic.
SBP and ESRD risk alone demonstrated a somewhat
J-shaped curve with a lower risk in the SBP 110 to 139
mm Hg range. However, this did not account for the
competing risk of mortality and thus, may be
misleading when ESRD alone is evaluated.
Our study population included large numbers
of diabetic patients and patients $70 years of age. The
stratiﬁed analyses in both DM and age $70 pop-
ulations demonstrated a similar U-shaped risk curve.
Clinical trials evaluating aggressive BP reduction
have focused more on DM populations, and it has
not been clear if those study results would apply to
hypertensive nondiabetic patients. In our study, pa-
tients with DM overall had better outcomes at lower
BP than did nondiabetic patients, but their optimal BP
were still within the 130 to 139 mm Hg systolic range.
Historically, lower observed BP has been associ-
ated with better survival from vascular disease and
mortality outcomes (3,5). Interventional studies that
reduced BP in extreme HTN populations have de-
monstrated signiﬁcant improvement in morbidity
and mortality in both DM and nondiabetic patients
(5–13,34). This has led to large population-based
initiatives to raise awareness about HTN and to
implement strategies for HTN control. The emphasishas been to treat on the assumption of “the lower
the better.” Even as lower has been observed as
better (3), it may not necessarily apply to the
“treated” HTN population.
The setting of the ideal BP targets in the HTN
population has not been satisfactorily addressed.
Whereas high BP is detrimental, the beneﬁts of
treatment have been demonstrated mostly at ach-
ieved SBP >130 mm Hg (5–13,34–36). Aggressive HTN
treatment to very low BP may have untoward conse-
quences and may be at the expense of greater costs
on the patients and the health delivery environment.
In fact, several studies have suggested worsened
outcomes with relatively lower treated BP (8,23),
whereas others have suggested that there may be
no proven beneﬁt of treating those with mild
HTN unless there is evidence of end-organ damage
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Treatment of hypertension reduces morbidity and
mortality, but optimal blood pressure targets have
not been clearly deﬁned.
COMPETENCY IN PATIENT CARE: Compared with
blood pressure ranges of 130 to 139 mm Hg systolic
and 60 to 79 mm Hg diastolic, both higher and lower
pressure ranges are associated with worse outcomes
in hypertensive patients on treatment.
TRANSLATIONAL OUTLOOK: Additional studies
are necessary to determine whether the target blood
pressure associated with optimal outcomes varies
with the type of antihypertensive therapy utilized.
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596(37,38). The recent 2014 evidence-based guidelines
for management of high blood pressure now suggest
higher BP goals and threshold for treatment in those
with DM, CKD, and age $60 years (39). However, we
are unaware of any recommendations cautioning on
thresholds for low treatment BP.
STUDY LIMITATIONS. The achieved BP may not
necessarily reﬂect the treated goal BP but may
instead represent a biomarker for a sicker population.
One example of this limitation is the disproportionate
prevalence of ischemic heart disease across the BP
ranges. The tested interactions between ischemic
heart disease and BP demonstrated signiﬁcance
implying that pre-existing cardiovascular disease
may affect the HR. Nevertheless, in separate analyses
of the populations with and without cardiovascular
disease, the HR across BP continued to demonstrate a
U-shaped curve.
Obesity was also highly prevalent in our popula-
tion with 43% having a BMI $30 kg/m2. Our cohort
also demonstrated an obesity paradox similar to
that described in the past in other high-risk pop-
ulations (40). Obesity had a protective effect where
those who were obese (BMI $30 kg/m2) had a
mortality/ESRD HR of 0.85 (95% CI: 0.83 to 0.88).
Furthermore, every BMI increase of 5 kg/m2was
associated with mortality/ESRD HR of 0.87 (95% CI:
0.86 to 0.89).
Because BP declines toward the end of life (41), the
mean BP over the observation period may have con-
founding effects, as they may reﬂect the processes
that lead to ESRD or death rather than the actual
treated BP. Indeed, the BP within 60 days of death
were signiﬁcantly lower than BP before death. We did
perform several sensitivity analyses to control for
such residual confounding. We used single baseline
BP values instead of mean BP over time, but we
continued to ﬁnd a similar BP curve. We also per-
formed Cox regression analyses, after excluding BP
within 60 days of mortality or ESRD. However, these
sensitivity analyses cannot account for confounding
due to reverse causality where the near end-of-life
state may lead to low BP.
The effect of medication treatment and duration on
outcomes is a confounder that cannot be accounted for
in this study. The different medicine classes and the
number of medicines may have had additional pleo-
tropic effects in addition to the BP-lowering effect.
There is also confounding by indication for patients
who received different medicine classes or numbers of
medicines that were not evaluated in our study.
Physician bias may have been another limitation as
patients that practitioners identiﬁed as more ill may
have been seenmore frequently and treated withmoreaggressive BP approaches. In addition, we were unable
to fully account for variables, such as smoking, diet,
and physical activity.
Despite these potential limitations, the strengths
of our study lie in the large, ethnically diverse, and
sex-balanced HTN population that included large
numbers of diabetic patients and elderly patients.
The clinical encounter information including vital
signs, medications, comorbidities, and utilization
data were reliably captured for the cohort. In addi-
tion, the standardized treatment approaches for HTN
lessen some of the confounding from heterogeneity
among the individual practitioners.
CONCLUSIONS
We found that treated HTN patients with BP in the
range of 130 to 139 mm Hg systolic and 60 to 79
mm Hg diastolic experienced the lowest risk for the
composite outcome of mortality and ESRD. Patients
with either higher or lower BP departing from these
ranges were found to be at greater risk for these
outcomes. Whereas current U.S. guidelines empha-
size the upper limits of therapeutic goals (39), the
potential dangers of overtreatment may need to be
considered. In the current HTN management envi-
ronment, both escalation and withdrawal of medica-
tions may be appropriate for optimal outcomes in an
HTN population.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
John J. Sim, Division of Nephrology and Hyperten-
sion, Kaiser Permanente Southern California, Los
Angeles Medical Center, 4700 Sunset Boulevard, Los
Angeles, California 90027. E-mail: John.j.sim@kp.org.
J A C C V O L . 6 4 , N O . 6 , 2 0 1 4 Sim et al.
A U G U S T 1 2 , 2 0 1 4 : 5 8 8 – 9 7 Blood Pressure and Mortality/ESRD Risk
597RE F E RENCE S1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE,
Roccella EJ. Trends in hypertension prevalence,
awareness, treatment, and control rates in United
States adults between 1988-1994 and 1999-
2004. Hypertension 2008;52:818–27.
2. Egan BM, Zhao Y, Axon RN. US trends in preva-
lence, awareness, treatment, and control of hy-
pertension, 1988-2008. JAMA 2010;303:2043–50.
3. Lewington S, Clarke R, Qizilbash N, Peto R,
Collins R. Age-speciﬁc relevance of usual blood
pressure to vascular mortality: a meta-analysis
of individual data for one million adults in
61 prospective studies. Lancet 2002;360:
1903–13.
4. Whelton PK, He J, Appel LJ, et al. Primary
prevention of hypertension: clinical and public
health advisory from The National High Blood
Pressure Education Program. JAMA 2002;288:
1882–8.
5. Klag MJ, Whelton PK, Randall BL, et al. Blood
pressure and end-stage renal disease in men. N
Engl J Med 1996;334:13–8.
6. Group VACS. Effects of treatment on morbidity
in hypertension. Results in patients with diastolic
blood pressures averaging 115 through 129 mm Hg.
JAMA 1967;202:1028–34.
7. SHEP. Prevention of stroke by antihypertensive
drug treatment in older persons with isolated
systolic hypertension. Final results of the Systolic
Hypertension in the Elderly Program (SHEP). SHEP
Cooperative Research Group. JAMA 1991;265:
3255–64.
8. Turnbull F, Neal B, Ninomiya T, et al. Effects of
different regimens to lower blood pressure on
major cardiovascular events in older and younger
adults: meta-analysis of randomised trials. BMJ
2008;336:1121–3.
9. Group UPDS. Tight blood pressure control and
risk of macrovascular and microvascular compli-
cations in type 2 diabetes: UKPDS 38. UK Pro-
spective Diabetes Study Group. BMJ 1998;317:
703–13.
10. Hansson L, Zanchetti A, Carruthers SG, et al.
Effects of intensive blood-pressure lowering and
low-dose aspirin in patients with hypertension:
principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. HOT Study
Group. Lancet 1998;351:1755–62.
11. Julius S, Kjeldsen SE, Weber M, et al. Outcomes
in hypertensive patients at high cardiovascular risk
treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet
2004;363:2022–31.
12. Staessen JA, Fagard R, Thijs L, et al. Rando-
mised double-blind comparison of placebo and
active treatment for older patients with isolated
systolic hypertension. The Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators. Lancet
1997;350:757–64.
13. Staessen JA, Gasowski J, Wang JG, et al. Risks
of untreated and treated isolated systolic hyper-
tension in the elderly: meta-analysis of outcome
trials. Lancet 2000;355:865–72.14. Cushman WC, Evans GW, Byington RP, et al.
Effects of intensive blood-pressure control in
type 2 diabetes mellitus. N Engl J Med 2010;362:
1575–85.
15. Appel LJ, Wright JT Jr., Greene T, et al.
Intensive blood-pressure control in hypertensive
chronic kidney disease. N Engl J Med 2010;363:
918–29.
16. JATOS Study Group. Principal results of the
Japanese trial to assess optimal systolic blood
pressure in elderly hypertensive patients (JATOS).
Hypertens Res 2008;31:2115–27.
17. Ogihara T, Saruta T, Rakugi H, et al. Target
blood pressure for treatment of isolated systolic
hypertension in the elderly: valsartan in elderly
isolated systolic hypertension study. Hypertension
2010;56:196–202.
18. Benavente OR, Coffey CS, Conwit R, et al.
Blood-pressure targets in patients with recent
lacunar stroke: the SPS3 randomised trial. Lancet
2013;382:507–15.
19. Wright JT Jr., Bakris G, Greene T, et al. Effect
of blood pressure lowering and antihypertensive
drug class on progression of hypertensive kidney
disease: results from the AASK trial. JAMA 2002;
288:2421–31.
20. Iseki K, Miyasato F, Tokuyama K, et al. Low
diastolic blood pressure, hypoalbuminemia, and
risk of death in a cohort of chronic hemodialysis
patients. Kidney Int 1997;51:1212–7.
21. Port FK, Hulbert-Shearon TE, Wolfe RA, et al.
Predialysis blood pressure and mortality risk in a
national sample of maintenance hemodialysis pa-
tients. Am J Kidney Dis 1999;33:507–17.
22. Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood
Pressure and Mortality in U.S. Veterans With
Chronic Kidney DiseaseA Cohort Study. Annals of
Internal Medicine 2013;159:233–42.
23. Yusuf S, Teo KK, Pogue J, et al. Telmisartan,
ramipril, or both in patients at high risk for
vascular events. N Engl J Med 2008;358:1547–59.
24. Bangalore S, Messerli FH, Wun CC, et al. J-curve
revisited: An analysis of blood pressure and car-
diovascular events in the Treating to New Targets
(TNT) Trial. Eur Heart J 2010;31:2897–908.
25. Ruggenenti P, Perna A, Loriga G, et al. Blood-
pressure control for renoprotection in patients
with non-diabetic chronic renal disease (REIN-2):
multicentre, randomised controlled trial. Lancet
2005;365:939–46.
26. Verma S, Gupta M, Holmes DT, et al. Plasma
renin activity predicts cardiovascular mortality in
the Heart Outcomes Prevention Evaluation (HOPE)
study. Eur Heart J 2011;32:2135–42.
27. Koebnick C, Langer-Gould AM, Gould MK,
et al. Sociodemographic characteristics of mem-
bers of a large, integrated health care system:
comparison with US Census Bureau data. Perm J
2012;16:37–41.
28. Bhandari SK, Pashayan S, Liu IL, et al. 25-
hydroxyvitamin D levels and hypertension rates.
J Clin Hypertens (Greenwich) 2011;13:170–7.29. Levey AS, Stevens LA, Schmid CH, et al. A new
equation to estimate glomerular ﬁltration rate.
Ann Intern Med 2009;150:604–12.
30. Sim JJ, Bhandari SK, Shi J, et al. Characteristics
of resistant hypertension in a large, ethnically
diverse hypertension population of an integrated
health system. Mayo Clin Proc 2013;88:1099–107.
31. Sim JJ, Bhandari SK, Shi J, et al. Plasma renin
activity (PRA) levels and antihypertensive drug
use in a large healthcare system. Am J Hypertens
2011;25:379–88.
32. Sim JJ, Handler J, Jacobsen SJ, Kanter MH.
Systemic implementation strategies to improve hy-
pertension: the Kaiser Permanente Southern Cali-
fornia experience. Can J Cardiol 2014;30:544–52.
33. Go AS, Chertow GM, Fan D, MCCulloch CE,
Hsu CY. Chronic kidney disease and the risks of
death, cardiovascular events, and hospitalization.
N Engl J Med 2004;351:1296–305.
34. Zanchetti A. Blood pressure targets of anti-
hypertensive treatment: up and down the J-sha-
ped curve. Eur Heart J 2010;31:2837–40.
35. Perry HM Jr., Davis BR, Price TR, et al. Effect of
treating isolated systolic hypertension on the risk
of developing various types and subtypes of
stroke: the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 2000;284:465–71.
36. Cooper-DeHoff RM, Gong Y, Handberg EM,
et al. Tight blood pressure control and cardiovas-
cular outcomes among hypertensive patients with
diabetes and coronary artery disease. JAMA 2010;
304:61–8.
37. DeFelice A,Willard J, Lawrence J, et al. The risks
associated with short-term placebo-controlled
antihypertensive clinical trials: a descriptive meta-
analysis. J Hum Hypertens 2008;22:659–68.
38. Diao D, Wright JM, Cundiff DK, Gueyfﬁer F.
Pharmacotherapy for mild hypertension. Cochrane
Database Syst Rev 2012;8:CD006742.
39. James PA, Oparil S, Carter BL, et al. 2014
Evidence-based guideline for the management of
high blood pressure in adults: report from the panel
members appointed to the Eighth Joint National
Committee (JNC 8). JAMA 2014;311:507–20.
40. Romero-Corral A, Montori VM, Somers VK,
et al. Association of bodyweight with total
mortality and with cardiovascular events in cor-
onary artery disease: a systematic review of
cohort studies. Lancet 2006;368:666–78.
41. Diehr PH, Thielke SM, Newman AB, Hirsch C,
Tracy R. Decline in health for older adults: ﬁve-year
change in 13 key measures of standardized health.
J Gerontol A Biol Sci Med Sci 2013;68:1059–67.
KEY WORDS blood pressure goals,
hypertension treatment, mortality risk,
renal failure risk, treatment riskAPPENDIX For supplemental tables and a
ﬁgure, please see the online version of
this article.
